On December 27, the second-generation recombinant protein COVID-19 vaccine developed by Sinopharm Zhongsheng Biotechnology Research Institute/National Engineering Research Center for Novel Vaccines (hereinafter referred to as "China Institute of Biology") has been approved for emergency use by the UAE Ministry of Health and Prevention, which is also the world's first second-generation COVID-19 vaccine approved for emergency use. Li Qiming, president of the China Institute of Biology, said in an interview with the Global Times reporter on the 29th that the second-generation recombinant protein new crown vaccine is significantly better than the control vaccine group for the neutralizing antibody level of the Aumicron strain. The vaccine will be used in the UAE as a booster for people who have received two doses of Sinopharm's China Bio-COVID-19 inactivated vaccine.
The second-generation recombinant protein COVID-19 vaccine is developed by the scientific research team of the Chinese Academy of Biological Research and has independent intellectual property rights. Based on the first generation of recombinant protein NEW CROWN vaccine, the R&D team has newly designed and developed a second-generation recombinant protein NEW CROWN vaccine through comprehensive analysis and evaluation of the immune evasion ability and evolutionary laws of various variant strains, which is the only second-generation vaccine approved for emergency use.
Li Qiming introduced that the recombinant protein new crown vaccine is based on the natural structural characteristics of the new coronavirus spike protein (S protein) receptor binding region (RBD), using structural biology and computational biology independent design and development, with clear targets and strong pertinence, which can induce the body to produce targeted neutralizing antibodies, thereby blocking the binding of the virus and the recipient cells and playing a protective role.
Li Qiming said that the first generation of recombinant protein new crown vaccine developed by the China Academy of Biology was designed according to the prototype strain of the new crown virus, and the target antigen is a triperized RBD that is close to the natural structure of the virus. The development of the second-generation vaccine began in April 2021, which is a broad-spectrum vaccine developed for the high variability of the virus based on the mature technical platform of the first-generation vaccine. The difference between second-generation vaccines and first-generation vaccines is mainly reflected in the design of target antigens, and the goal of second-generation vaccine research and development is to have a broad spectrum, so the technical platform of computational structure vaccines is fully utilized in the research, and the broad spectrum of the vaccine is improved through computational modeling and molecular simulation design, and the efficiency of research and development is also guaranteed.
▲The R&D personnel of the China Institute of Biological Research are in the laboratory
For the Current Widespread Concern about the Aomi Kerong variant with strong immune escape ability, Li Qiming said that the current research data show that after receiving the second-generation recombinant protein new crown vaccine, the neutralizing antibody levels of the vaccinators are also significantly better than those of the control vaccine group The recombinant' sequential vaccination method will greatly improve the immune response level and persistence of the vaccinators, stimulate the human body to produce high-level neutralizing antibodies against prototype strains and major variant strains, and also have the potential to protect various variant strains. ”
The Chinese biocombinant protein COVID-19 vaccine has been clinically studied in nearly 4,000 subjects in the UAE. This vaccine was approved by the Uae Ministry of Health and Prevention, becoming the world's first approved emergency use of the second-generation new crown vaccine, and will be used as a reinforcing needle after the sequential vaccination, its promotion progress and application prospects in China have also aroused concern from all walks of life, in this regard, Li Qiming said that Sinopharm China Bio is in accordance with the clinical program design, phased summary of data, to provide research and judgment basis and data support for domestic vaccination strategies.